{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03826433",
      "OrgStudyIdInfo": {
        "OrgStudyId": "SCLnow-XY-04"
      },
      "Organization": {
        "OrgFullName": "Sclnow Biotechnology Co., Ltd.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis",
      "OfficialTitle": "Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosis"
    },
    "StatusModule": {
      "StatusVerifiedDate": "October 2020",
      "OverallStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "October 1, 2018",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "June 2022",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2022",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "January 14, 2019",
      "StudyFirstSubmitQCDate": "January 30, 2019",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "February 1, 2019",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "September 21, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "September 23, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Sclnow Biotechnology Co., Ltd.",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "Evaluation the safety of using human umbilical mesenchymal stem cells to treat patients with hepatitis B cirrhosis.\nObserve the curative effect of patients with hepatitis B cirrhosis who use human umbilical mesenchymal stem cells to treat.\nExplore the possible mechanism of human umbilical mesenchymal stem cells to treat patients with hepatitis B cirrhosis.",
      "DetailedDescription": "This experimental use umbilical cord mesenchymal stem cells in treatment of decompensated hepatitis B cirrhosis to evaluate its safety and efficacy,\n\nThis experimental is mainly aimed at people aged 18-60 years old, regardless of gender and with body mass index (BMI) between 19-25kg/m2 (including boundary value). It was decided into treatment group and control group to evaluate the effectiveness and safety of mesenchymal stem cells by peripheral intravenous injection."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Hepatitis B"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Hepatitis B Cirrhosis, mesenchymal stem cell"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "20",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Treatment Group",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Mesenchymal Stem Cells : through peripheral intravenous slowly, every time 6*10^7 (30ml) Other medication of Treatment Group: before the30min of first time to inject stem cells, Intravenous methylprednisone 20mg. All patients require oral nucleoside drugs resistant hepatitis B virus treatment.Use stem cell therapy, by Peripheral iv, 6 * 10 ^ 7 (30 ml)",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Peripheral iv"
              ]
            }
          },
          {
            "ArmGroupLabel": "Control Group",
            "ArmGroupType": "No Intervention",
            "ArmGroupDescription": "Control Group: Using basic contrast ."
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Peripheral iv",
            "InterventionDescription": "6*10^7 cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Treatment Group"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Validity evaluation by detection of the Model for end-stage Liver Disease score of participants",
            "PrimaryOutcomeDescription": "After finish the mesenchymal stem cell treatment, observe the change in baseline outcome measures.\n\n40 or more - 71.3% observed mortality 30-39 - 52.6% observed mortality 20-29 - 19.6% observed mortality 10-19 - 6.0% observed mortality <9 - 1.9% observed mortality",
            "PrimaryOutcomeTimeFrame": "12 month"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Safety evaluation by detecting Blood routine",
            "SecondaryOutcomeDescription": "To calculate the number of hemocyte and related protein (e.g. erythrocyte, lymphocyte, and hemoglobin) after mesenchymal stem cell treatment",
            "SecondaryOutcomeTimeFrame": "12 month"
          },
          {
            "SecondaryOutcomeMeasure": "Validity evaluation by detection of the child-pugh of participants",
            "SecondaryOutcomeDescription": "After finish the mesenchymal stem cell treatment, observe the change in baseline outcome measures.\n\nPoints Class One-year survival Two-year survival 5-6 A 100% 85% 7-9 B 80% 60% 10-15 C 45% 35%",
            "SecondaryOutcomeTimeFrame": "12 month"
          }
        ]
      },
      "OtherOutcomeList": {
        "OtherOutcome": [
          {
            "OtherOutcomeMeasure": "Validity evaluation by detection of the coagulation function of participants",
            "OtherOutcomeDescription": "After finish the mesenchymal stem cell treatment, observe the change of Prothrombin Time and International Normalized Ratio (PT/INR) in baseline outcome measures.\n\nThe time is around 12-13 seconds, the INR in absence of anticoagulation therapy is 0.8-1.2.",
            "OtherOutcomeTimeFrame": "12 month"
          },
          {
            "OtherOutcomeMeasure": "Imaging examination",
            "OtherOutcomeDescription": "After finish the mesenchymal stem cell treatment, observe the Computed Tomography (CT).",
            "OtherOutcomeTimeFrame": "12 month"
          },
          {
            "OtherOutcomeMeasure": "Imaging examination",
            "OtherOutcomeDescription": "Fibro-Touch examination",
            "OtherOutcomeTimeFrame": "12 month"
          },
          {
            "OtherOutcomeMeasure": "Safety evaluation by detecting adverse events and serious adverse events",
            "OtherOutcomeDescription": "To evaluate the changes of safety indexes before and after mesenchymal stem cell treatment",
            "OtherOutcomeTimeFrame": "12 month"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nAge 18-60 years old, gender not limited, body mass index (BMI) between 19-25 kg/m2, including boundary value;\nThe diagnosis of hepatitis B cirrhosis was in line with the 2015 American society of hepatology (AASLD) guidelines for the treatment of chronic hepatitis B, and the liver function grade was child-pugh B or child-pugh C, with a score range of 7-12 points, and Model for End-Stage Liver Disease score≤21 points.\nHave not received stem cell therapy in the recent 6 months;\nSubjects will be able to sign the informed consent in accordance with the study procedures and instructions.\n\nExclusion Criteria:\n\nInsufficiency of vital organs, such as heart, kidney and lung;\nEnd-stage cirrhosis with severe complications, including but not limited to: hepatic encephalopathy, gastrointestinal bleeding,Severe bleeding tendency, massive ascites, etc.\nConcomitant peritonitis, pneumonia, or other types of infection not under control;\nHave a history of severe allergic reaction or allergy to two or more kinds of food or medicine;\nPositive serum HIV antibody and syphilis antibody;\nAlpha fetoprotein>400ng/mL with primary liver cancer or without imaging evidence;\nChronic liver disease and cirrhosis are caused by non-chronic hepatitis B virus infection, or other factors except chronic hepatitis B virus infection ;\nPatients with severe mental illness and cognitive impairment;",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "60 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Lei Guo, doctor",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "861064368977",
            "CentralContactEMail": "georgeguo@sclnow.com"
          },
          {
            "CentralContactName": "Xuegong Fan, doctor",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "86731-84327392",
            "CentralContactEMail": "xgfan@hotmail.com"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Xuegong Fan, doctor",
            "OverallOfficialAffiliation": "Xiangya Hospital of Central South University",
            "OverallOfficialRole": "Study Director"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Xiangya Hospital Central South University",
            "LocationStatus": "Recruiting",
            "LocationCity": "Changsha",
            "LocationState": "Hunan",
            "LocationZip": "410008",
            "LocationCountry": "China",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "ShaLing Li, doctor",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "8613975186154"
                },
                {
                  "LocationContactName": "Xuegong Fan, doctor",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "86731-84327392",
                  "LocationContactEMail": "xgfan@hotmail.com"
                }
              ]
            }
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000006506",
            "ConditionMeshTerm": "Hepatitis A"
          },
          {
            "ConditionMeshId": "D000006509",
            "ConditionMeshTerm": "Hepatitis B"
          },
          {
            "ConditionMeshId": "D000006505",
            "ConditionMeshTerm": "Hepatitis"
          },
          {
            "ConditionMeshId": "D000005355",
            "ConditionMeshTerm": "Fibrosis"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000008107",
            "ConditionAncestorTerm": "Liver Diseases"
          },
          {
            "ConditionAncestorId": "D000004066",
            "ConditionAncestorTerm": "Digestive System Diseases"
          },
          {
            "ConditionAncestorId": "D000006525",
            "ConditionAncestorTerm": "Hepatitis, Viral, Human"
          },
          {
            "ConditionAncestorId": "D000014777",
            "ConditionAncestorTerm": "Virus Diseases"
          },
          {
            "ConditionAncestorId": "D000007239",
            "ConditionAncestorTerm": "Infections"
          },
          {
            "ConditionAncestorId": "D000004769",
            "ConditionAncestorTerm": "Enterovirus Infections"
          },
          {
            "ConditionAncestorId": "D000010850",
            "ConditionAncestorTerm": "Picornaviridae Infections"
          },
          {
            "ConditionAncestorId": "D000012327",
            "ConditionAncestorTerm": "RNA Virus Infections"
          },
          {
            "ConditionAncestorId": "D000086982",
            "ConditionAncestorTerm": "Blood-Borne Infections"
          },
          {
            "ConditionAncestorId": "D000003141",
            "ConditionAncestorTerm": "Communicable Diseases"
          },
          {
            "ConditionAncestorId": "D000018347",
            "ConditionAncestorTerm": "Hepadnaviridae Infections"
          },
          {
            "ConditionAncestorId": "D000004266",
            "ConditionAncestorTerm": "DNA Virus Infections"
          },
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M10255",
            "ConditionBrowseLeafName": "Liver Cirrhosis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8747",
            "ConditionBrowseLeafName": "Hepatitis B",
            "ConditionBrowseLeafAsFound": "Hepatitis B",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M8743",
            "ConditionBrowseLeafName": "Hepatitis",
            "ConditionBrowseLeafAsFound": "Hepatitis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M8744",
            "ConditionBrowseLeafName": "Hepatitis A",
            "ConditionBrowseLeafAsFound": "Hepatitis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M7637",
            "ConditionBrowseLeafName": "Fibrosis",
            "ConditionBrowseLeafAsFound": "Cirrhosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10259",
            "ConditionBrowseLeafName": "Liver Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8035",
            "ConditionBrowseLeafName": "Gastrointestinal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6407",
            "ConditionBrowseLeafName": "Digestive System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8762",
            "ConditionBrowseLeafName": "Hepatitis, Viral, Human",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16674",
            "ConditionBrowseLeafName": "Virus Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9435",
            "ConditionBrowseLeafName": "Infections",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5520",
            "ConditionBrowseLeafName": "Communicable Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M7082",
            "ConditionBrowseLeafName": "Enterovirus Infections",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M12897",
            "ConditionBrowseLeafName": "Picornaviridae Infections",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14301",
            "ConditionBrowseLeafName": "RNA Virus Infections",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M19640",
            "ConditionBrowseLeafName": "Hepadnaviridae Infections",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6594",
            "ConditionBrowseLeafName": "DNA Virus Infections",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC06",
            "ConditionBrowseBranchName": "Digestive System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC01",
            "ConditionBrowseBranchName": "Infections"
          }
        ]
      }
    }
  }
}